Novocure grew from Professor Yoram Palti’s basement laboratory in Haifa, where he began exploring electric fields as a way to target cancer cells in 2000. Today, the international oncology company develops and commercializes Tumor Treating Fields therapy for patients facing some of the most aggressive solid tumors, while continuing research into wider applications.
Iovance Biotherapeutics, IncIovance Biotherapeutics develops and manufactures personalized tumor-infiltrating lymphocyte (TIL) cell therapies for people with cancer. Its 136,000-square-foot Iovance Cell Therapy Center in Philadelphia makes TIL therapy using proprietary processes, including a 22-day Gen 2 process; the company also markets Amtagvi and Proleukin.PHILADELPHIA, PA
AdaptimmuneAdaptimmune develops engineered T-cell receptor (TCR) therapies designed to direct the immune system against cancer, with a particular focus on solid tumors. Based in Oxfordshire, the company has built its platform over more than 15 years to identify cancer targets, enhance T-cell receptor affinity and screen candidates for potential off-target binding.541714PHILADELPHIA, PA
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA